

1 ***The SARS-CoV-2 receptor-binding domain expressed in Pichia***  
2 ***pastoris as a candidate vaccine antigen***

3 Miladys Limonta-Fernández<sup>a,&</sup>, Glay Chinaa-Santiago<sup>a,&</sup>, Alejandro Miguel Martín-Dunn  
4<sup>a,&</sup>, Diamile Gonzalez-Roche<sup>a,&</sup>, Monica Bequet-Romero<sup>a,&</sup>, Gabriel Marquez-Perera<sup>a,&</sup>,  
5 Isabel González-Moya<sup>a</sup>, Camila Canaan-Haden-Ayala<sup>a</sup>, Ania Cabrales-Rico<sup>a</sup>, Luis  
6 Ariel Espinosa-Rodríguez<sup>a</sup>, Yassel Ramos-Gómez<sup>a</sup>, Ivan Andujar-Martínez<sup>a</sup>, Luis  
7 Javier González-López<sup>a</sup>, Mariela Perez de la Iglesia<sup>a</sup>, Jesus Zamora-Sanchez<sup>a</sup>, Otto  
8 Cruz-Sui<sup>b</sup>, Gilda Lemos-Pérez<sup>a</sup>, Gleysin Cabrera-Herrera<sup>a</sup>, Jorge Valdes-Hernández<sup>a</sup>,  
9 Eduardo Martinez-Diaz<sup>c</sup>, Eulogio Pimentel-Vazquez<sup>c</sup>, Marta Ayala Avila<sup>a</sup>, Gerardo  
10 Guillén-Nieto<sup>a,d,&,\*</sup>

11  
12<sup>a</sup> Center for Genetic Engineering and Biotechnology, CIGB, Ave. 31 E/ 158 y 190, La  
13 Habana 10600, Cuba.

14<sup>b</sup> Civilian Defense Scientific Research Center, Carretera de Jamaica y Autopista  
15 Nacional, San José de las Lajas, Mayabeque, Cuba

16<sup>c</sup> Biotechnology and Pharmaceutical Industries Group, BioCubaFarma, Ave.  
17 Independencia 8126, esq. a Calle 100. Boyeros. La Habana, Cuba.

18<sup>d</sup> Latin American School of Medicine, Calle Panamericana Km 3 1/2, Playa, La Habana  
19 11600, Cuba.

20<sup>&</sup> These authors contributed equally to this work and should be considered as co-first  
21 authors

22

23 \* **Corresponding author:**

24 Gerardo Guillén-Nieto Ph.D.

25 Biomedical Research Direction

26 Center for Genetic Engineering and Biotechnology

27 Ave. 31 E/ 158 y 190, La Habana 10600, Cuba

28 E-mail: [gerardo.guillen@cigb.edu.cu](mailto:gerardo.guillen@cigb.edu.cu)

29

30 **Abbreviations:** Receptor-binding domain (RBD), coronavirus disease 2019 (COVID-  
31 19), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), angiotensin-  
32 converting enzyme 2 (ACE2), peripheral blood mononuclear cells (PBMC), Interleukin 2  
33 (IL-2), Interleukin 4 (IL-4), Interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF $\alpha$ ),  
34 interferon gamma (IFN $\gamma$ ), non-human primates (NHP), Chinese hamster ovary cells  
35 (CHO), baby hamster kidney cells (BHK21), human embryonic kidney cells (HEK293T),  
36 immobilized metal ion affinity chromatography (IMAC), reversed-phase chromatography  
37 (RP), circular dichroism (CD), optical density (OD), viral neutralization titer (VNT).

38 **Highlights**

- 39 • The RBD protein (C-RBD-H6 PP) is expressed with high purity in *P. pastoris*.
- 40 • Physico-chemical characterization confirms the right folding of the protein.
- 41 • The recombinant protein shows high antigenicity with sera from convalescents.
- 42 • The sera from animals inhibit the RBD-ACE2 binding and neutralize the virus.

- 43 • The C-RBD-H6 protein stimulates IFN $\gamma$ , IL-2, IL-6, IL-4, and TNF $\alpha$  in mice.

#### 44 **1. Abstract**

45 The effort to develop vaccines based on economically accessible technological  
46 platforms available by developing countries vaccine manufacturers is essential to  
47 extend the immunization to the whole world population and to achieve the desired herd  
48 immunity, necessary to end the COVID-19 pandemic. Here we report on the  
49 development of a SARS-CoV-2 receptor-binding domain (RBD) protein, expressed in  
50 yeast *Pichia pastoris*. The RBD was modified with addition of flexible N- and C-terminal  
51 amino acid extensions aimed to modulate the protein/protein interactions and facilitate  
52 protein purification. Fermentation with yeast extract culture medium yielded 30–40  
53 mg/L. After purification by immobilized metal ion affinity chromatography and  
54 hydrophobic interaction chromatography, the RBD protein was characterized by mass-  
55 spectrometry, circular dichroism, and binding affinity to angiotensin-converting enzyme  
56 2 (ACE2) receptor. The recombinant protein shows high antigenicity with convalescent  
57 human sera and also with sera from individuals vaccinated with the Pfizer-BioNTech  
58 mRNA or Sputnik V adenoviral-based vaccines. The RBD protein stimulates IFN $\gamma$ , IL-2,  
59 IL-6, IL-4, and TNF $\alpha$  in mice secreting splenocytes from PBMC and lung CD3+ enriched  
60 cells. Immunogenicity studies with 50  $\mu$ g of the recombinant RBD formulated with alum,  
61 induce high levels of binding antibodies in mice and non-human primates, assessed by  
62 ELISA plates covered with RBD protein expressed in HEK293T cells. The mouse sera  
63 inhibited the RBD binding to ACE2 receptor in an *in-vitro* test and show neutralization of  
64 SARS-CoV-2 infection of Vero E6 cells. These data suggest that the RBD recombinant

65 protein expressed in yeast *P. pastoris* is suitable as a vaccine candidate against  
66 COVID-19.

67 **Keywords:** SARS-CoV-2, *P. pastoris*, COVID-19, RBD, subunit vaccine

## 68 **1. Introduction**

69 The pandemic caused by SARS-CoV-2 has demonstrated the need to modify the way  
70 that public health, the governmental role, and international cooperation in science and  
71 health have been functioning up to now. It will not be possible to end the pandemic if the  
72 desired herd immunity is not achieved and for that it is necessary to vaccinate the vast  
73 majority of the world's population in the shortest possible time. It is not enough for  
74 industrialized countries to be vaccinated, so the contribution of the developing countries'  
75 vaccine manufacturers is more than welcome.

76 Cuba is an example of a global vision of public health and stands out for the strength of  
77 its biotechnology industry where one of the main achievements is the production of the  
78 Hepatitis B recombinant vaccine in yeast *P. pastoris* since 1991 [1-3] and the inclusion  
79 in the national immunization program since 1992. As a result, the incidence of acute  
80 hepatitis B in the country has decreased down to less than 50 cases and acute hepatitis  
81 B in children under 5 years old has not been reported since the year 2000 [4].

82 Therefore, it is feasible to select this technological platform for the development of a  
83 vaccine candidate against SARS-CoV-2.

84 The mammalian cell expression systems as Chinese hamster ovary cells (CHO), baby  
85 hamster kidney cells (BHK21), human embryonic kidney cells (HEK293T), and mouse-

86 derived myeloma cell lines (NS0, SP2/0) are preferred for the expression of complex  
87 proteins for its capacity of proper post-translational modifications equivalent to that of  
88 humans, even though the selection of this recombinant protein production platform is  
89 limited by its low growth and productivity, and high production cost due to the relevant  
90 nutrient requirement [5]. The potential viral contamination of culture medium has also  
91 limited the use of the mammalian cell expression systems in large-scale production [6].

92 *Pichia pastoris* is one of the biotechnological platforms for the production of  
93 recombinant proteins that overcome several limitations of bacteria as expression  
94 system, such as protein aggregation and misfolding, production of toxic  
95 lipopolysaccharides, lack of posttranslational modifications, and frequent protein  
96 degradation due to the presence of proteases [7]. N-glycans in yeast secreted proteins  
97 are highly mannosylated while mammalian proteins have hybrid sugar composition. *P.*  
98 *pastoris* uses methanol, an inductor of the strong and tightly regulated AOX1 promoter  
99 as an exclusive carbon source. Therefore methanol can be used to drive protein  
100 expression altogether that it is reached an efficient secretion of the recombinant  
101 proteins [8]. On the other hand, the advantages of protein production by *P. pastoris* lie  
102 in the fact that the mechanism of protein expression in these microorganisms is close to  
103 the ones in mammalian cells and include the right protein folding in the endoplasmic  
104 reticulum, protein secretion by Kex2 as signal peptidase and low contamination with  
105 host proteins due to its limited production of endogenous secretory proteins [9], which  
106 simplifies and makes the purification process more feasible. Other significant  
107 advantages of yeast include growth speed, and easy genetic manipulation allowing

108 linearized foreign DNA to be inserted at high efficiency in a chromosome via cross  
109 recombination to generate stable cell lines [10].

110 The receptor-binding domain of SARS-CoV-2 is a glycosylated 25 kDa protein domain  
111 spanning residues N<sub>331</sub>-K<sub>529</sub> of the spike protein, including eight cysteine residues  
112 forming four disulfide bonds. The domain contains two glycosylation sites (N<sub>331</sub> and  
113 N<sub>343</sub>) and a central twisted antiparallel beta-sheet formed by five strands with secondary  
114 structure short helices and loops [11]. Although glycosylation plays a fundamental role  
115 in the immunogenicity and stability of the RBD protein, the variability of the composition  
116 and heterogeneity in size of the sugar chains may not influence the receptor binding  
117 capacity [12]. Probably, for this reason the glycosylation introduced by *P. pastoris* more  
118 distant from mammalian cells and therefore more distant to the humans could contribute  
119 to the protein immunogenicity. RBD mediates cell entry through ACE2 host receptor and  
120 the levels of RBD binding antibodies strongly correlate with neutralizing antibodies in  
121 patients. Even more, the neutralizing antibody kinetics in patients mirrored the kinetics  
122 of RBD antibody development [13]. Since RBD upon infection is the main target of  
123 neutralizing antibodies, it has become the focus of vaccine design.

124 The SARS-CoV-2 RBD has been expressed at high levels in *P. pastoris* as a suitable  
125 vaccine candidate against COVID-19 [8;14;15]. The comparison between RBD obtained  
126 from *P. pastoris* and HEK293T mammalian cells by CD and tryptophan fluorescence  
127 shows that proteins were properly folded as well as that they have similar temperature  
128 stability despite differences in glycosylation of both expression platforms.

129 Here, we report the design of an RBD protein vaccine candidate, its expression in *P.*  
130 *pastoris* yeast, protein purification, the physico-chemical characterization and the

131 capacity of the protein to elicit ACE2 binding inhibition antibodies, and neutralizing  
132 response in mice and monkeys. Our approach differs from the previously reported  
133 expression of RBD in *P. pastoris* [8] in the inclusion of the RBD glycosylation sites  
134 maintaining the advantage of the glycosylation capacity of *P. pastoris*.

## 135 **2. Materials and Methods**

### 136 ***2.1. Biological reagents, protein codification and serum panels***

137 Human and murine RBD and ACE2 receptor chimeric proteins (hFc-RBD, mFc-RBD,  
138 hFc-ACE2, mFc-ACE2) were supplied by the Center of Molecular Immunology (CIM,  
139 Havana, Cuba). All the chimeric proteins were purified by protein-A based purification of  
140 the supernatant of stable transduce HEK293T cells and eluted in PBS. hFc-RBD was  
141 conjugated with peroxidase (HRP) and henceforth named hFcRBD-HRP. H6-RBD was  
142 produced as *E. coli* inclusion bodies [16], while RBD-H6 and C-RBD-H6 HEK were  
143 secreted to the supernatant of stably transduced HEK293T. All three proteins were  
144 purified by IMAC and the final buffer was exchanged to PBS. N-terminal end segment  
145 (C), and C-terminal end six histidine tag (H6), added to the central RBD protein  
146 sequence in a different protein constructions are codified as C-RBD-H6. Acronyms PP  
147 and HEK next to the protein code refers to the expression system when *P. pastoris* or  
148 HEK293T cells where used.

149 Different human sera used as controls include sera from volunteers vaccinated with  
150 Pfizer/BioNtech or Gamaleya's Sputnik V (Gam-COVID-Vac) vaccine, and sera from  
151 convalescent patients. All individuals gave their writing informed consent for the use of  
152 their serum.

153 **2.2. Construction of *Pichia pastoris* strains expressing RBD from SARS-CoV-2 (C-**  
154 **RBD-H6 PP)**

155 A sequence coding for residues 331-530 of the Spike protein of SARS-CoV-2 strain  
156 Wuhan-Hu-1 (NCBI Acc. No. YP\_009724390) with the appropriate N- and C-terminal  
157 extensions was codon-optimized for *S. cerevisiae* using J-Cat [17] and cloned in-frame  
158 with the KEX2 cleavage site of the pre-pro MAT $\alpha$  sequence of pPICZ $\alpha$ A (Invitrogen,  
159 USA), placing it under transcriptional control of the *P. pastoris* AOX1 promoter. After  
160 sequence verification, a representative clone was used to transform *P. pastoris* strain X-  
161 33 [18], selecting transformants by plating in YPD agar at Zeocin<sup>TM</sup> concentrations of  
162 100, 200, 400, and 800  $\mu$ g/mL. Three transformants from the plate with the highest  
163 concentration of Zeocin<sup>TM</sup> were randomly picked, purified by further streaking on YPD-  
164 Zeocin<sup>TM</sup>, and used to prepare small seed banks. The seed banks were used in turn to  
165 inoculate small-scale (50 mL) BMGY cultures [18] that were induced after 24 h of  
166 growth at 28 °C by the addition of 0.5 % methanol. Culture supernatants were analyzed  
167 at 96 h post-induction by SDS-PAGE and Western blotting with an anti-His6 antibody  
168 (Promega, USA).

169 **2.3. Fermentation**

170 Fermentation was carried out in a 75-liters Chemap fermenter (Germany) with a working  
171 volume of 50 L of fermentation medium containing per liter of culture 8.8 mL of 85 %  
172 phosphoric acid, 6.92 g MgSO<sub>4</sub>·7H<sub>2</sub>O, 1.23 g (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 16.77 g K<sub>2</sub>HPO<sub>4</sub>,  
173 0.46 g CaCl<sub>2</sub>·2H<sub>2</sub>O, 32.3 mL of 98% glycerol, 4.61 g yeast extract, 4 mL histidine  
174 solution, 5 mL of 400X vitamin base solution (1 g L<sup>-1</sup> myo-inositol, 0.8 g L<sup>-1</sup> D-calcium



175 pantothenate, 0.8 g L<sup>-1</sup> thiamine hydrochloride, 0.8 g L<sup>-1</sup> pyridoxol hydrochloride, 0.2 g  
176 L<sup>-1</sup> nicotinic acid, 0.8 mg L<sup>-1</sup> D (+) Biotin), and 1 mL of sterile-filtered trace 1000X  
177 element solution (6 g L<sup>-1</sup> CuSO<sub>4</sub>.5H<sub>2</sub>O, 0.415 g L<sup>-1</sup> KI, 3 g L<sup>-1</sup> MnSO<sub>4</sub>.H<sub>2</sub>O, 1 g L<sup>-1</sup>  
178 Na<sub>2</sub>MoO<sub>4</sub>.2H<sub>2</sub>O, 0.1 g L<sup>-1</sup> H<sub>3</sub>BO<sub>3</sub>, 20 g L<sup>-1</sup> ZnSO<sub>4</sub>.7H<sub>2</sub>O, 65 g L<sup>-1</sup> FeSO<sub>4</sub>.7H<sub>2</sub>O, 10 mL.  
179 conc.H<sub>2</sub>SO<sub>4</sub>) was added after autoclaving [19]. After inoculation of the bioreactor with 4  
180 L of pre-culture, the temperature was maintained at 30 °C and the pH at 4.75 by  
181 pumping in a liquid ammonia solution. When a dissolved oxygen peak or a widening of  
182 the pH peaks is observed, the fed-batch phase is started with glycerol 50 % at 540 mL/h  
183 for 2-3 h. After one hour, the temperature is lowered to 25 ° C and raises the pH to 5.5.  
184 When the 50 % glycerol increase is exhausted, 800 mL of methanol is added at  
185 maximum flow of the peristaltic pump. The induction phase with methanol is started at  
186 an initial flow of 240 mL/h, 4 h later the flow is increased to 380 mL/h, and then at 480  
187 mL/h. This last flow is maintained until the end of fermentation (38-44 h).

#### 188 **2.4. Protein purification**

189 After 48 h of fermentation in a yeast extract culture medium, the culture was harvested,  
190 and cells were removed by centrifugation retention time between 5 -10 min at 15000  
191 rpm at 4 °C. The fermentation supernatant was filtered in tandem conditions from 8 µm  
192 – 3 µm – 0.45 µm using cellulose filters. The supernatant was concentrated with a  
193 tangential flow filtration system with 30 kDa Hydrosart® membrane (Sartorius,  
194 Germany), besides buffer exchanged was carried out against PBS buffer containing 5  
195 mM of imidazole. The IMAC column (Chelating Sepharose™ FF, Cytiva) was  
196 equilibrated in the same buffer and the sample was loaded and sequentially washed by  
197 using 30 column volumes of PBS containing 10 mM and 20 mM imidazole. Elution was

198 carried out by increasing the concentration of imidazole up to 250 mM in the equilibrium  
199 buffer. The eluted protein was applied to a RP C4 column (Tosohaas, Japan) with  
200 dimensions 50 mm in diameter by 250 mm long for a resin volume of 500 mL and with a  
201 particle size of 15 to 20  $\mu\text{m}$ . The column is coupled to a Shimadzu model LC-20AP  
202 semi-preparative HPLC purification system. The column was equilibrated with 0.5 %  
203 TFA solution, and protein was eluted by using a linear gradient of 1 % TFA solution (RP  
204 solution A) and acetonitrile with 0.5 % TFA (RP solution B) from 32 to 45 % solution B in  
205 40 minutes. The protein elutes between 35 and 37 % of solution B, approximately in one  
206 column volume. The fraction collected with the purified protein was concentrated by  
207 tangential flow filtration system with a 10 kDa Hydrosart® membrane and pooled  
208 aseptically using a 0.22  $\mu\text{m}$  and stored at  $-20\text{ }^{\circ}\text{C}$ .

## 209 **2.5. ESI-MS analysis of the deglycosylated C-RBD-H6 PP protein**

210 The volume equivalent to 100  $\mu\text{g}$  of the protein dissolved in PBS (pH 7.2) was  
211 deglycosylated with 1  $\mu\text{L}$  of PNGase-F (500 units, New England Biolabs) in presence of  
212 0.5 M guanidine hydrochloride and 5 mM N-ethylmaleimide during 2 h at  $37\text{ }^{\circ}\text{C}$ . An  
213 aliquot of 10  $\mu\text{g}$  of deglycosylated protein was desalted by using ZipTip C18 (Millipore)  
214 and the elution was loaded into the metal-coated nanocapillary for ESI-MS analysis.  
215 The remaining deglycosylated protein was digested by using an in-solution buffer-free  
216 trypsin digestion protocol previously reported [20] and adapted to the analysis of SARS-  
217 CoV-2 RBD proteins by introducing some modifications that provide full-sequence  
218 coverage and detection of post-translational modifications in a single ESI-MS spectrum

219 [16]. Other experimental conditions for ESI-MS analysis are similar to those reported  
220 previously [16].

## 221 **2.6. Surface plasmon resonance experimental procedure**

222 The interaction between mFc-ACE2 fusion protein and the recombinant C-RBD-H6 PP  
223 was monitored by SPR using a BIACORE X (GE Health-care) at 25 °C in a multi-cycle  
224 mode. Briefly, mFc-ACE2 was immobilized on a Protein A biosensor chip (GE Health-  
225 care) according to the manufacturer's protocol through the flow cell 1 (FC1). The FC2  
226 was used as the reference cell. The real-time response of the C-RBD-H6 PP over the  
227 immobilized mFc-ACE2 was recorded by duplicate in a concentration range from 15 to  
228 2000 nM, at 10  $\mu$ L/min flow rate for 120 s, while the dissociation took place for another  
229 120 s. The running buffer was PBS (pH = 7.2). After each cycle the chip was  
230 regenerated using pH = 2.0 glycine buffer. The equilibrium dissociation constant  
231 (binding affinity,  $K_D$ ) was estimated with the BIAevaluation® software (GE Healthcare)  
232 using the Langmuir 1:1 interaction model. At least five curves were taken into account  
233 for kinetics calculations.

## 234 **2.7. Structural Analysis by Circular Dichroism (CD) Spectroscopy**

235 CD spectra were acquired in a Jasco J-1500 CD spectrometer (Jasco, Japan). All  
236 measurements were carried out at 24 °C, the far UV CD spectra were studied at 100  
237  $\mu$ g/ml protein concentration (a 10 fold dilution in water of the stock solution) using a  
238 1mm quartz cuvette. The near UV CD spectra were studied at the protein concentration  
239 of the stock solution in 20 mM pH 7.4 Tris buffer using a quartz cuvette of 10 mm path  
240 length. The spectra of the corresponding solution were subtracted. The far UV CD

241 spectra were further analyzed by the BeStSel method [21;22] to estimate the secondary  
242 structure content of the protein and the results were compared with the values derived  
243 from the 3D coordinates of the crystallographic structure of the spike protein of SARS-  
244 CoV-2 (PDB file 6yla) using DSSP method [23] implemented in Whatif program package  
245 [24].

## 246 **2.8. Animals and immunization schedules**

247 Three different animal species were used for evaluation of immunogenicity of the C-  
248 RBD-H6 PP protein: BALB/c mice, Sprague–Dawley (SD) rats, and African green  
249 monkeys (*Chlorocebus aethiops sabaeus*). Six- to eight-week-old female BALB/c mice,  
250 and male and female SD rats were used for the study and housed in the animal facility.  
251 The experimental protocols were approved by the Ethical Committee on Animal  
252 Experimentation of the Center for Genetic Engineering and Biotechnology (CIGB,  
253 Havana, Cuba) and the Center for Production of Laboratory Animals (CENPALAB,  
254 Bejucal, Cuba).

255 The immunogen content per 500  $\mu$ L: 50  $\mu$ g of C-RBD-H6 PP protein adjuvated with 0.3  
256 mg of aluminum hydroxide gel (Alhydrogel  $\text{\textcircled{R}}$ ) in phosphate buffer (0.28 mg of disodium  
257 hydrogen phosphate, 0.31 mg of sodium dihydrogen phosphate dihydrate, 4.25 mg of  
258 sodium chloride).

259 *BALB/c mice*: Immunogenicity in mice was evaluated using a three-dose schedule with  
260 a 50  $\mu$ g dose by intraperitoneal route with a 7 and 14 days interval before the second  
261 and third doses respectively. Blood was collected a week after the first boost and 7 and

262 14 days after the second boost. The number of animals per group, age, and gender of  
263 the animals are described in individual experiments.

264 *Sprague Dawley rats*: Immunogenicity of the C-RBD-H6 PP protein was tested in 20 SD  
265 rats (10 male and 10 female) during chronic toxicology study, with a 9 µg dose  
266 administered by the intramuscular route once a week, for 10 consecutive weeks for a  
267 total of 90 µg. Animals were bled three days after the last dose.

268 *Chlorocebus aethiops sabaeus* non-human primates: NHP ages between 3 to 6 years  
269 and with 2-7 kg of weight were kept at the animal's facility at the CENPALAB. A total of  
270 20 NHP were randomly assigned to 3 groups including the placebo (2 animals/gender,  
271 total 4), the low dose (50 µg, 3 animals/gender, total 6), and the high dose (100 µg, 5  
272 animals/gender, total 10). Seven days post-1st and 2nd boosting and after overnight  
273 fasting, monkeys were sedated by intramuscular injection of ketamine hydrochloride (10  
274 mg/kg) and bled from the femoral vein.

275 Specific anti-RBD titers and the inhibition of its interaction with ACE2 receptor were  
276 evaluated using ELISA. Live SARS-CoV-2 neutralization was assessed using a  
277 microneutralization assay.

## 278 **2.9. Serum antibodies evaluation**

### 279 *Antibody detection by ELISA*

280 The reactivity of sera from immunized animals was determined by ELISA. Briefly, 0.25  
281 µg of RBD protein produced in HEK293T cells (Center for Molecular Immunology,  
282 Havana) was used to coat 96-well microtiter plates (Corning Costar, Acton, MA) in 0.1  
283 M sodium carbonate buffer (pH 9.6) at 4 °C overnight. After the plates were blocked

284 with 2 % skim milk, 0.05 % Tween 20, serially diluted mouse, rat or NHP sera or control  
285 monoclonal antibodies SS-1, SS-4, SS-7 and SS-8 (Center for Genetic Engineering and  
286 Biotechnology, Sancti Spiritus, Cuba), were added and incubated at 37 °C for 2 h in 0.2  
287 % skim milk, 0.05 % Tween 20 in PBS, followed by six washes with PBS containing  
288 0.05 % Tween 20. Bound antibodies were detected with horseradish peroxidase-  
289 conjugated goat anti-mouse IgG (SIGMA, USA), anti-Rat IgG (SIGMA, USA) anti-  
290 human IgG (1:10000, Jackson, USA) at 37 °C for 1 h, followed by washes. The reaction  
291 was detected after the addition of 3,3-5,5-tetramethylbenzidine and quantified using a  
292 microplate reader at 450 nm (BMG Labtech, Germany). This assay was also used for  
293 the evaluation of RBD antigenicity using sera from immunized animals, and from  
294 subjects that received Pfizer-BioNTech or Sputnik V vaccines, or are COVID-19  
295 convalescents.

#### 296 *RBD to ACE2 plate-based binding assay*

297 A competitive ELISA was performed to determine the inhibitory activity of the anti-RBD  
298 polyclonal sera on the binding of the hFc-ACE2 coated plates to an hFc-RBD-HRP  
299 conjugate. Briefly, the wells of ELISA plates were coated with 0.25 µg of recombinant  
300 hFc-AEC2 as described above. A mixture containing an hFc-RBD-HRP conjugate and  
301 serial dilutions of the sera were pre-incubated for 1h at 37 °C. A hundred microliters of  
302 the mixture were added to hFc-ACE2 coated plates and further incubated for 90 min at  
303 37 °C. The binding of the HRP tagged RBD to the receptor was detected after the  
304 addition of 3,3-5,5-tetramethylbenzidine and reading at 450 nm. A similar assay was  
305 used to characterize the ability of the C-RBD-H6 PP and C-RBD-H6 HEK proteins to  
306 block the interaction of hFc-RBD-HRP with coated hFc-ACE2.

## 307 **2.10. Microneutralization of live SARS-CoV-2 virus in Vero E6**

308 The neutralization antibody titers were detected by a traditional virus microneutralization  
309 assay (MN50) using SARS-CoV-2 (CUT2010-2025/Cuba/2020 strain). Vero E6 cells  
310 ( $2 \times 10^4$  per well) were seeded in 96-well plates one night before use. Animals' sera were  
311 inactivated at 56 °C for 30 min. The samples were prepared by two-fold serial sera  
312 dilutions in the Eagle's Minimal Essential Medium (MEM, Gibco, UK) containing 2 %  
313 (v/v) fetal bovine serum (Capricorn, Germany). SARS-CoV-2 strain at 100 TCID<sub>50</sub> was  
314 incubated in the absence or presence of diluted sera for 1 h at 37 °C. Afterward, Vero  
315 E6 cell were overlaid with virus suspensions. At 96 h post-infection, the cells were  
316 inspected for signs of cytopathogenic effects (CPE) by optical microscopy and stained  
317 with neutral red (Sigma, USA). After three washes neutral red was dissolved in lysis  
318 solution (50 % ethanol, 1 % acetic acid) for 15 min at 25 °C, and optical density (OD)  
319 was detected at 540 nm. The highest serum dilution showing an OD value greater than  
320 the cut-off was considered as the neutralization titer. The cut-off value is calculated as  
321 the average of the OD of the cell control wells divided by two. The viral neutralizing  
322 titers (VNT<sub>50</sub>) were calculated as the highest serum dilution at which 50 % of the cells  
323 remain intact according to neutral red incorporation in the control wells (no virus added).

## 324 **2.11. Cellular immune response**

325 Long-term cellular immune response was evaluated in BALB/c mice using  
326 subcutaneous administration of a formulation containing an equal antigen to alum ratio.  
327 Animals receive 25 µg of the C-RBD-H6 PP antigen by the subcutaneous route in a 100  
328 µL volume in a 0-14-35 days schedule. Blood samples were evaluated two weeks after

329 the last immunization and animals were euthanized 3 months later to assess for  
330 systemic and lung resident cells response to *in vitro* antigen recall. Splenocytes were  
331 flushed out by perfusion using gentamycin supplemented PBS and lung resident  
332 lymphocytes were extracted after elimination of remnant blood by left auricular perfusion  
333 with PBS. To detach leukocytes from lung tissue, a lung dissociation enzyme mix (130-  
334 095-927, Miltenyi, Germany) was used according to manufacturer instructions and using  
335 a cell dissociator (GentleMACS Octo Dissociator, Miltenyi). CD3<sup>+</sup> cells were further  
336 selected from lung suspension using negative selection with magnetic beads (130-095-  
337 130, Miltenyi) and both lung CD3<sup>+</sup> cells and splenocytes live cells were counted using a  
338 flow cytometer (CyFlow, Sysmex, Germany).

339 For the re-stimulation assays, splenocyte or lung selected CD3<sup>+</sup> suspensions were  
340 diluted to 10x10<sup>6</sup> CD3<sup>+</sup> live cells/mL and 50 µL of each sample was seeded in two 96-  
341 well U bottom tissue culture plates. Cells were re-stimulated with 50 µL of 20 µg/mL C-  
342 RBD-H6 PP, or just media (unstimulated) for 72 h, and the supernatant was analyzed at  
343 1:2 dilution using Biolegend Deluxe cytokine kits for IL-2 (431004), IFN $\gamma$  (430804), IL-6  
344 (431304), IL-4 (431104) and TNF $\alpha$  (430204) following manufacturer's instructions. Cells  
345 were transferred at that point to anti IFN $\gamma$  coated ELISpot plates (Mabtech, Germany)  
346 and results were analyzed 24 h later according to established procedures.

#### 347 **2.12. ELISpot assay with samples from previous naturally infected individuals**

348 PBMCs from subjects with previous natural infection with SARS-CoV-2 were isolated  
349 from 7 mL of whole blood collected using CPT tubes (Becton Dickinson, US), and store  
350 in liquid nitrogen until analyzed. After overnight resting the cells in Optimizer media



351 (Gibco, Invitrogen, US) CD3<sup>+</sup> live cells were counted using flow cytometry and seeded  
352 on activation plates at  $5 \times 10^4$  cells per well with 10 µg/mL of the recombinant C-RBD-H6  
353 PP protein for 72 h. After transferring the cells to anti-IFN $\gamma$  pre-coated plates (Mabtech,  
354 GE). The amounts of T cells secreting the cytokine were detected after 20 h of  
355 incubation as recommended by the manufacturer. All individuals gave their writing  
356 informed consent for the use of their samples.

### 357 **2.13. Statistical analysis**

358 Prism 8.4.3 software was used to generate dose-response curves for ELISA test and to  
359 calculate EC<sub>50</sub> values when needed. One way-ANOVA with Sidak's multiple  
360 comparisons tests-was used to determine the significance of differences and Spearman  
361 test was used to assess for parameters correlations. Wilcoxon matched paired test was  
362 used to perform paired analyzes for both stimulated/non-stimulated samples, the  
363 evolution of RBD specific titers and inhibition of ACE2 binding.

## 364 **3. Results**

### 365 **3.1. Design of the C-RBD-H6 expression cassette**

366 Recombinant C-RBD-H6 PP protein was designed as a potential subunit vaccine  
367 candidate against SARS-CoV-2 displaying e modular structure consists of: a) a globular  
368 central – RBD- domain comprising residues N<sub>331</sub>-K<sub>529</sub> of the spike protein, b) additional  
369 N- and C-terminal segments including polar and flexible linkers rich in Glycine and  
370 Serine (Gly<sup>9</sup>-Ser<sup>15</sup> and Gly<sup>215</sup>-Ser<sup>229</sup>). The N- and C-terminal extensions are aimed to  
371 modulate potential protein-protein interactions and facilitate protein purification through

372 a high accessible hexa-Histidine tag (His<sup>232</sup>-His<sup>237</sup>). Topologically, the extensions are  
373 located in the opposite site of the protein respect to the receptor binding motif and its  
374 presence should sterically hinder potential aggregation problems associated to the  
375 presence of the exposed and disulfide bonded Cys<sup>76</sup> and Cys<sup>210</sup>. (The C-RBD-H6 PP  
376 protein sequence is included as a supplemental material S1).

### 377 **3.2. Expression and purification of the C-RBD-H6 PP**

378 A construct for the expression in *P. pastoris* of the RBD from SARS-CoV-2 under  
379 control of the AOX1 promoter, denominated pPICZ $\alpha$ -CtagRBDH6, was prepared as  
380 described in Materials and Methods and used to obtain RBD-expressing yeast clones.  
381 Fig. 1 (lanes A-C) shows the result of the analysis of culture supernatants from 3  
382 randomly selected clones after induction with methanol. There is a noticeable smear in  
383 the supernatant from all three clones, ranging between 25 kDa and 50 kDa, that is  
384 absent from the control transformed with the empty vector (lane V, Fig. 1), and resolves  
385 into a ladder when probed by Western blotting with an anti-His6 antibody. Considering  
386 the presence of three-potential N-glycosylation sites in the sequence of C-RBD-H6 PP  
387 protein; and also that its molecular mass calculated from its cDNA sequence is 26 kDa  
388 the presence of a broad and diffuse band detected on SDS-PAGE analysis suggest that  
389 the C-RBD-H6 PP is being secreted in all three cases as a N-glycosylated protein.  
390 Based on signal intensity in Western blotting, clone C was denominated X33-23 and  
391 selected for further work (Fig. 1). The C-RBD-H6 PP protein was purified from the  
392 supernatant following the procedures described in Materials and Methods, by IMAC,  
393 followed by polishing using a RP to obtain a final preparation with high purity. After  
394 purification, the C-RBD-H6 PP was obtained with a final yield between 30–40 mg/L of

395 culture medium, with more than 98% of purity at the end of the downstream process  
396 (Fig. 2 and 3).

397 **3.3. ESI-MS analysis for determining the accurate molecular mass, the verification**  
398 **of the amino sequence and the assessment of disulfide bonds of the**  
399 **deglycosylated C-RBD-H6 PP protein**

400 The C-RBD-H6 PP protein deglycosylated with PNGase-F was analyzed by ESI-MS  
401 and the multiply charged spectrum is shown in Fig. 4.A. Deconvolution of this ESI-MS  
402 spectrum (Fig. 4.B) showed a very intense signal at 26069.54 Da. This molecular mass  
403 agrees very well with the calculated molecular mass (26069.87 Da) for the C-RBD-H6  
404 PP considering the presence of four intramolecular disulfide bonds and the two out the  
405 three potential N-glycosylation sites transformed into Asp residues due to the action of  
406 PNGase-F. Also a low-abundance signal (see star in Fig. 4.B) indicates that a minor  
407 fraction of this molecule is devoid of the extension of four N-terminal amino acids (-  
408 NSWF) not belonging to the RBD protein.

409 To verify the amino acid sequence as well as the disulfide bonds the deglycosylated  
410 protein was digested with trypsin using an in-solution buffer-free digestion protocol  
411 developed in our group [16;20]. ESI-MS analysis of the tryptic peptides is shown in Fig.  
412 4.C. Full-sequence coverage of C-RBD-H6 PP was verified and the assignment for  
413 signals observed in this mass spectrum is summarized in Table 1. ESI-MS/MS analysis  
414 of the signal detected at  $m/z$  1399.64, 4+ confirmed that Asn<sup>331</sup> and Asn<sup>343</sup> (two out the  
415 three potential N-glycosylation sites) were transformed into Asp residues by the action  
416 of PNGase F (see underlined residues in the Table). The four disulfide bonds (C<sub>336</sub>-C<sub>361</sub>,  
417 C<sub>379</sub>-C<sub>432</sub>, C<sub>391</sub>-C<sub>525</sub> and C<sub>480</sub>-C<sub>488</sub>) present in the native S protein of SARS-CoV-2 were

418 also detected in this ESI-MS spectrum (Fig. 4.C and Table 1). Tryptic peptides  
419 containing free cysteine residues and S-S scrambling variants were not detected.

420 ESI-MS analysis of the deglycosylated C-RBD-H6 PP protein and its derived tryptic  
421 peptides confirmed that N-glycans in its structure increased considerably its molecular  
422 mass by SDS-PAGE analysis.

### 423 **3.4. Surface Plasmon Resonance characterization of the RBD-ACE2 binding** 424 **affinity**

425 As shown in Fig. 5, there was no appreciable signal in terms of response units (RU)  
426 when measurements were performed a non-related protein used as negative control for  
427 BIACORE experiments, immobilizing mFc-ACE2 ligand by Fc region on to a Prot A chip.  
428 In contrast, the association rate for C-RBD-H6 PP protein to mFc-ACE2 was  $5.4 \times 10^5 \text{ M}^{-1}$   
429  $\text{s}^{-1}$ , with a dissociation rate of  $7.7 \times 10^{-3} \text{ s}^{-1}$ . The equilibrium was reached between 25  
430 and 30 seconds, with an estimated dissociation constant of  $K_D = 14.3 \times 10^{-9} \text{ M}$ . The  
431 association/dissociation rates as well as  $K_D$  were in the expected ranges, according to  
432 the previously reported results for the RBD-ACE2 molecular interaction [25].

### 433 **3.5. Secondary structure analysis by CD Spectroscopy**

434 Fig. 6 shows the far UV CD spectrum of the C-RBD-H6 PP protein revealing  
435 characteristic bands similar to the observed in other recombinant RBD proteins reported  
436 previously [8], with maxima at 192 and 231 nm – due to the aromatic contribution - and  
437 minimum at 207 nm. Furthermore, as shown in Table 2 the secondary structure content  
438 of the protein estimated by BeStSel (7.9% helix, 28.7% beta - antiparallel, relaxed and

439 right-handed-, 12.9% turn y 50.5% others) is very similar to the values assigned using  
440 the 3D coordinates [11]. Moreover, as observed in Fig. 7 the near UV CD spectrum of  
441 the protein is well structured, with bands at 263, 269, 277, 281 and 299 nm, indicative of  
442 the presence of well-packed aromatic and cysteine residues as expected for a properly  
443 folded protein.

### 444 **3.6. Antigenicity analysis of C-RBD-H6 PP**

445 To confirm the antigenicity of the yeast-derived protein, several ELISA tests were  
446 performed with SS-1, SS-4, SS-7 and SS-8 anti-RBD monoclonal antibodies obtained  
447 immunizing with RBD-H6 HEK protein produced in the mammalian cells HEK293T. One  
448 of these monoclonal antibodies (SS-8) inhibits the protein binding to the ACE2 receptor  
449 with an IC<sub>50</sub> of 60 ng/mL. The binding to C-RBD-H6 PP protein was compared to the  
450 binding to C-RBD-H6 HEK as shown in Fig. 8.A,E. The reactivity does not differ  
451 between the two proteins. Human sera with high neutralization titers for live SARS-CoV-  
452 2 viral challenge of Vero E6 cells from eight COVID-19 naturally infected patients and  
453 seven individuals that already received Pfizer-BioNTech or Sputnik V complete vaccine  
454 schedules were incorporated into the testing panels. None properly folded C-RBD-H6  
455 protein produced as inclusion body in BL-21 *E coli* strain was used as a negative  
456 control. C-RBD-H6 PP protein obtained from yeast was able to maintain antigenicity  
457 comparable to the protein purified from mammalian cells (Fig. 8.B,F and C,G). Minimal  
458 signals were detected with the sera from animals immunized with RBD protein  
459 expressed in *E. coli*, corroborating the need for a correctly folded protein to ensure the  
460 exposition of immunodominant epitopes (data not shown). Further characterization was  
461 conducted using polyclonal sera from mice and NHP immunized with C-RBD-H6 PP

462 and C-RBD-H6 HEK proteins, and with known capacity to neutralize SARS-CoV-2  
463 infection. All polyclonal sera similarly detect the RBD protein expressed in both  
464 heterologous expression system (Fig. 8.D,H).

465 The C-RBD-H6 PP protein was also used to recall *in vitro* a cellular response in terms of  
466 IFN $\gamma$  secretion using ELISpot from PBMCs of COVID-19 naturally infected subjects with  
467 at least three months from hospital release. As shown in Fig. 8.I stimulation with 10  
468  $\mu$ g/mL of the yeast-produced protein induce IFN $\gamma$  secretion from COVID-19 naturally  
469 infected subjects PBMCs.

### 470 **3.7. Functionality of yeast-expressed RBD protein**

#### 471 *ACE2 receptor binding competition assay*

472 The functionality of the recombinant protein C-RBD-H6 PP was confirmed by the  
473 assessment of its ability to bind to the chimeric hFc-ACE2 receptor bound to ELISA  
474 plates and also to bind to the ACE2 receptor in Vero E6 cells both in solution or  
475 attached to the plate. To evaluate the binding of the protein to hFcACE-2, a serial two-  
476 fold dilution curve of the test protein starting from 100  $\mu$ g/mL was mixed with HEK293T  
477 produced hFc-RBD-HRP conjugate at a fixed concentration and added to hFc-ACE2  
478 coated plates. As shown in Fig. 9.A, two independent C-RBD-H6 PP protein  
479 preparations effectively displaced the hFc-RBD HEK in the same magnitude that the  
480 soluble hFc-ACE2 and the recombinant RBD-H6 HEK protein obtained in HEK293T  
481 cells. Two non-related chimeric proteins P64K-VEGFH6 (expressed in *E. coli*), and hFc-  
482 VEGFR2 (produced in HEK293T cells) were used as negative controls

483 A similar study was conducted on paraformaldehyde-fixed Vero E6 cells (Fig. 9.B) As  
484 expected, no displacement of biotinylated hFc-RBD from the cell membrane was  
485 observed in either case using as negative controls the non-related chimeric VEGF  
486 protein fused to the N-terminal of *Neisseria meningitidis* (P64K-VEGFH6) or the human  
487 Fc (VEGFR2-hFc), and 100 % of the signal was lost when the C-RBD-H6 PP protein,  
488 soluble hFc-ACE2 or mFc-ACE2 were added (Fig. 9.C). These results suggest that the  
489 yeast-expressed C-RBD-H6 PP protein can bind efficiently to the cell-surface ACE2  
490 receptor.

491 Further characterization of ACE2 binding was conducted in solution using yeast and  
492 mammalian-derived proteins coated in different concentrations in ELISA plates. ACE2  
493 EC-50 on RBD coated plates result in values ranging between 100 and 300 ng/mL in  
494 agreement with the values reported for commercial sources of RBD and with our data  
495 using RBD variants purified from HEK293T supernatant. Using the same system  
496 stability of the protein was verified by incubating the protein at 4 °C, 37 °C, and 50 °C  
497 for 2 h without significant loss in ACE2 binding activity (data not shown)

498 These results confirm the specific binding of the yeast-expressed RBD with SARS-CoV-  
499 2 receptor ACE2 either cell-bound or soluble, indicating that the antigen herein obtained  
500 is functional.

501 *Yeast-expressed RBD protein elicited RBD-ACE2 receptor binding inhibition and SARS-*  
502 *CoV-2 neutralizing antibodies in rodents and NHP*

503 To evaluate the immunogenicity of C-RBD-H6 PP protein, BALB/c mice were  
504 immunized thrice at 7 days intervals by the intraperitoneal route with 50µg of the

505 protein. The IgG antibody response in mice at days 21 and 35 shows that the C-RBD-  
506 H6 PP protein was able to induce antibody responses in ELISA coated with the RBD  
507 protein produced in mammalian HEK293T cells. Seroconversion was achieved a week  
508 after the first boost (Fig. 10.A). The administration of a second booster at day 21  
509 significantly increases both RBD-specific IgG titers and the inhibitory potential of the  
510 sera to reduce the protein binding to its cognate receptor ACE2 a fact that correlates  
511 with live SARS-CoV-2 neutralization (Fig. 10.B,C).

512 The C-RBD-H6 PP protein was also tested in SD rats using intramuscular  
513 administration of 9 µg every 7 days for 10 weeks. Assessment of IgG and RBD-ACE2  
514 receptor binding inhibition three days after the last immunization indicates high RBD-  
515 specific antibody titers that correlate with the inhibitory titer. The former also display a  
516 high correlation with the neutralization titer of live SARS-CoV-2 virus in Vero E6 cells  
517 (Fig. 10.D,F).

518 The C-RBD-H6 PP protein evaluation in NHP using short intramuscular administration  
519 schedule on days 0-14-28, and two dose levels indicate a dose-response effect with  
520 seroconversion of 83 % (5 of 6 animals) and 100% (the 10 animals) for the 50 µg and  
521 100 µg dose respectively after the first booster and a 100 % seroconversion in both  
522 schedules after the second booster. Total IgG titers increased to 44,240 StdU/mL and  
523 62,435 StdU/mL respectively for monkeys included in the low and high-dose groups. In  
524 both cases, the titers were significantly higher than those detected in the convalescent  
525 panel of sera. The geometric median ACE2 binding inhibition titer for 50 µg dose was  
526 1:230, while a significantly higher value of 1:705 was detected for the animals receiving  
527 the 100 µg dose. Both values were higher than those detected in a panel of COVID-19



528 convalescent subjects ( $p < 0.001$ , Kruskal-Wallis). The higher titers for the 100  $\mu\text{g}$  dose  
529 correlate with and enhancement in the inhibition of RBD-ACE2 binding for this group.  
530 The analysis of the neutralization titer of live SARS-CoV-2 virus in Vero E6 cells  
531 corroborates these findings, indicating that 50 $\mu\text{g}$  dose is sufficient to induce ACE2  
532 binding inhibition titers with an EC50 geometric mean of 1:66 serum dilution, a value 6  
533 times higher than the reported for the convalescent panel. A significant increase to  
534 1:141 in this parameter was detected for the 100  $\mu\text{g}$  dose pointing to a dose-related  
535 effect (Fig. 10.G,J).

536 The specific IgG antibody and the inhibition of RBD-ACE2 binding were only detected in  
537 C-RBD-H6 PP protein-inoculated animals but not in control animals. The immune  
538 responses evidenced the boosting effect and the specific dose-dependent effect, as  
539 compare to negative results for control animals.

#### 540 *Cellular response*

541 Cellular response recall was evaluated three months after the last immunization in  
542 BALB/c mice receiving subcutaneous doses of 25  $\mu\text{g}$  in alum in a 0-14-35 days  
543 schedule. The evaluation of the presence of a memory response in the animal's spleens  
544 indicates a significant induction of clones secreting IFN $\gamma$  in response to incubation with  
545 the C-RBD-H6 PP antigen. Furthermore, the analyses of the supernatant of the recall  
546 reaction point to the predominant induction of IFN $\gamma$  followed by IL-2, IL-6 and to a lower  
547 extend TNF $\alpha$  and IL-4 (Fig. 11). Our findings in the systemic compartment (Fig. 11.A)  
548 were similar to those found for CD3 $^+$  cells enriched from mice lungs (Fig. 11.B),

549 indicating that the response can also be recalled in the organ primarily affected by  
550 SARS-CoV-2 infection.

#### 551 **4. Discussion**

552 Despite the impressive development of prophylactic vaccines against COVID-19 and  
553 that several vaccines have reached the Emergency Use Authorization or  
554 Pharmaceutical Registry, there is not a sufficient supply of vaccines. In addition, the  
555 challenge of the continuous emergence of new mutant strains of the virus will require  
556 updating the antigen sequences included in the vaccines and administer booster doses  
557 to maintain the immunity of the population.

558 Results from this study demonstrate that it is possible to develop a vaccine candidate  
559 expressing RBD protein of SARS-CoV-2 using the yeast *P. pastoris*. The RBD was  
560 selected base on the state of the art evidence of the main contribution of the epitopes of  
561 RBD to the neutralization activity of the sera [13;26-28]

562 Moreover neutralizing antibody responses generated after immunization with Pfizer-  
563 BioNtech or Moderna vaccines of previously infected subjects, are mainly due to anti-  
564 RBD antibodies. The sera depletion of antibodies targeting the RBD abrogates sera  
565 neutralization capacity [29]

566 Optimal conditions for the production of a recombinant protein in *P. pastoris* expression  
567 system differ according to the target protein. Indeed, we were able to obtain 30-40 mg/L  
568 of the RBD with more than 98% of purity, close to the yield obtained in previous report  
569 by Arbeitman C.R., et al [8], an essential condition to develop a vaccine candidate. In  
570 addition to the protein yield, it is important the sugar composition. In *P. pastoris* the

571 glycosylation pattern is characterized by the high mannose content. Mannosylation  
572 enhances activation of antigen-presenting cells like macrophages and dendritic cells,  
573 functioning as immunopotentiator while increases the antigen immunogenicity  
574 compared with its nonglycosylated counterparts [30]. The ionic interactions dependent  
575 on sugar composition also could help to stabilize RBD structure.

576 Our results on the affinity of the *P. pastoris* recombinant protein C-RBD-H6 PP by the  
577 receptor comply with those of other authors performing binding assays in BIACORE for  
578 the interaction pair RBD-ACE2 [31-33]. It means that probably the subunit vaccine  
579 based on C-RBD-H6 PP may elicit an effective antibody response against SARS-CoV-  
580 2, avoiding the virus entry and replication by blocking RBD-ACE2 interaction in real  
581 SARS-CoV-2 infection context.

582 The correct glycosylated protein during the transit in the endoplasmic reticulum and  
583 Golgi apparatus, go to the secretory pathway. If the protein is unable to fold properly is  
584 degraded in the cytosol. This mechanism guarantees that only properly folded proteins  
585 are secreted [8;34]. Our results demonstrated the presence of four intramolecular  
586 disulfide bonds identical to those present in the native RBD of SARS-CoV-2. These  
587 results as well as the secondary structure determined by CD spectroscopy confirm the  
588 right folding of the C-RBD-H6 PP.

589 Remarkably despite the known difference in the sugar composition of the protein  
590 expressed in *P. pastoris* compared to the expression systems in mammals, the  
591 antigenicity of the protein is similar both with polyclonal sera from mice and monkeys  
592 immunized with the recombinant protein, such as with human sera from individuals with  
593 natural coronavirus infection or vaccinated with the Pfizer-BioNTech or Sputnik V

594 vaccines against SARS-CoV-2. The C-RBD-H6 PP protein also stimulated cellular  
595 response mediated by IFN $\gamma$  secretion in lymphocytes isolated from convalescent  
596 subjects. The C-RBD-H6 PP protein also inhibited the RBD binding to the ACE2  
597 receptor in a competitive ELISA regardless of whether the RBD receptor was obtained  
598 recombinant or it is found directly in the membrane of Vero E6 cells. In the same  
599 manner, the sera from mice, rats and NHP immunized with C-RBD-H6 PP protein  
600 inhibited the RBD-ACE2 receptor binding and neutralize the SARS-CoV-2 in  
601 microneutralization tests.

602 The need for the accelerated development of the vaccine candidate during the  
603 pandemic, led to the neutralizing activity of the NHP sera being evaluated just one week  
604 after the third dose, reaching titers comparable to the panel of convalescent sera used  
605 as a control. It is known that a long time for bleeding would lead to the maturation and  
606 selection of B cell clones producing high avidity antibodies and consequently higher  
607 neutralizing titers.

## 608 **Conclusions**

609 Optimal conditions for the production of a recombinant protein in *P. pastoris* expression  
610 system differ according to the target protein. Indeed, we were able to obtain 30-40 mg/L  
611 of the RBD with more than 98% of purity.

612 Our ESI-MS results demonstrated the presence of four intramolecular disulfide bonds  
613 identical to those present in the native RBD of SARS-CoV-2, and the CD spectrum of  
614 the protein indicates the presence of well-packed aromatic and cysteine residues.  
615 These results together with the high receptor binding affinity in BIACORE assays  
616 confirm the right folding of the C-RBD-H6 PP protein.

617 The C-RBD-H6 PP antigenicity and the capacity of the sera from immunized mice, rats  
618 and NHP to inhibited the RBD-ACE2 receptor binding and neutralize the live virus  
619 infection to Vero E6 cells, points to the feasibility of the protein as a vaccine candidate.

## 620 **Funding**

621 This work was supported with funds from the BioCubaFarma, the Center for Genetic  
622 Engineering and Biotechnology, and by the Grant of the National Science and  
623 Technology Program - Biotechnology, Pharmaceutical Industry and Medical  
624 Technologies, of the Ministry of Science and Technology, project code PN385LH007-  
625 048. The Civilian Defense Scientific Research Center supported the microneutralization  
626 assays.

## 627 **Authors Contributions**

628 GGN: provided original ideas and study concept and design, data curation, analysis and  
629 interpretation of data, and drafting, review and editing of the final version of the  
630 manuscript and studies supervision. MLF: contributed to analysis and interpretation of  
631 data, study design, review of the manuscript and studies supervision. LJGL: contributed  
632 to ESI-MS study design, acquisition of data, analysis and interpretation of data, and  
633 drafting and review of the manuscript. LAER, IAM and YRG: performed the ESI-MS  
634 studies, acquisition of data, analysis and interpretation of data. GCH: performed  
635 glycosylation studies. ACR: performed drafting and execution of Biacore studies. GMP:  
636 performed the protein purification studies. MPI and JZS: performed fermentation  
637 studies. GCS: provided original idea and drafting of the genetic construction, and  
638 performed structural analysis experiments by CD spectroscopy. AMMD: provided  
639 original ideas and performed the genetic construction and review of the manuscript. and

640 DGR: performed the genetic construction and protein expression experiments. MBR:  
641 provided original ideas, study designs, analysis and interpretation of data, drafting and  
642 review of the manuscript, graphic and statistical processing and execution of  
643 antigenicity, immunogenicity and cellular response studies. IGM and CCHA: performed  
644 antigenicity, immunogenicity studies and analysis of cellular response in mouse, rat,  
645 and NHP. OCS: study design and supervision of the microneutralization experiments.  
646 GLP: contributed to analytical procedures and donor patients selection and evaluation  
647 of the immunological and functional response. JVH, EMD, EPV and MAA: study  
648 concept and supervision.

#### 649 **Disclosure**

650 MLF, MBR, AMMD, DGR, ACR, GCS, GMP, EPV, MAA and GGN are co-authors of the  
651 Center for Genetic Engineering and Biotechnology patent application comprising the C-  
652 RBD-H6 PP protein as a vaccine antigen against SARS-CoV-2.

653 All authors approved integrally the final article.

#### 654 **Acknowledgment**

655 The authors acknowledge Dr. Gabriel Padron and Dr. Diana Garcia del Barco Herrera  
656 for their writing assistance. We also thank Dr. Gertrudis Rojas, Dr. Tays Hernández  
657 and Dr. Belinda Sanchez from the Center for Molecular Immunology for the recombinant  
658 mFc-RBD and hFc-RBD chimeric proteins.

659

## 660 **Figure Legends**

661 **Fig. 1. Analysis of culture supernatants from randomly selected RBD-secreting *P.***  
662 ***pastoris* clones.** In all cases 10  $\mu$ L of each sample were analyzed under reducing  
663 conditions. Panel A: Coomassie Blue-stained 12.5 % SDS-PAGE; panel B: Western  
664 blotting of an identical gel with an anti-His tail antibody. Lane V: Strain transformed with  
665 the empty vector. Lanes A, B and C: clones transformed with the RBD plasmid.

666 **Fig. 2. RP-HPLC.** Analysis of C-RBD-H6 PP protein produced in *Pichia pastoris*, with  
667 98.6 % of purity; analyzed on a reversed phase C8 Vydac analytical column. The  
668 gradient is shown with a blue line.

669 **Fig. 3. Protein electrophoresis.** Coomassie Blue stained 12,5 % SDS-PAGE gel of 10  
670  $\mu$ g of the purified C-RBD-H6 PP under reducing conditions. Lane 1: C-RBD-H6 PP  
671 protein; Lane 2 Molecular weight markers.

672 **Fig. 4. ESI-MS spectra.** (A) Multiply-charged and (B) deconvoluted ESI-MS spectra of  
673 C-RBD-H6 PP protein previously N-deglycosylated with PNGase-F. The parenthesis in  
674 (B) shows the expected molecular mass considering the presence of four intramolecular  
675 disulfide bonds and the Asn<sup>331</sup> and Asn<sup>343</sup> transformed into Asp residues by the  
676 PNGase F during the deglycosylation step. (C) ESI-MS spectrum of the tryptic peptides  
677 generated by an in-solution buffer-free trypsin digestion protocol of the N-  
678 deglycosylated C-RBD-H6 PP protein. The star in (B) and (C) indicates the low-  
679 abundance species that do not contain the four residues (-NWSF) located at the N-  
680 terminal end. Nt and Ct-His<sub>6</sub> represents the N-terminal end and the His<sub>6</sub>-tag C-terminal  
681 end peptides of C-RBD-H6 PP protein, respectively.

682 **Fig. 5. SPR analysis from C-RBD-H6 PP protein obtained in *P. pastoris* interacting**  
683 **with mFc-ACE2 receptor in a single-cycle BIACORE experiment.** (A) Sensorgrams  
684 corresponding to one of the replicates of the protein dissolved in PBS, pH = 7.2, (B)  
685 Non-related protein (also expressed in yeast), used as negative control for the  
686 interaction with immobilized mFc-ACE2 cell receptor. As expected, there were no  
687 significant signals for the protein used as negative control; compared to the curves  
688 obtained for C-RBD-H6 PP protein in the same experimental conditions (similar axis  
689 scale is shown).

690 **Fig. 6. Far UV CD spectrum of the C-RBD-H6 PP protein.**

691 **Fig. 7. Near UV CD spectrum of the C-RBD-H6 PP protein.** Bands at 263, 269, 277,  
692 281 and 299 nm, indicate the presence of well packed aromatic and cystine residues.

693 **Fig. 8. Antigenicity of the RBD protein produced in *P. pastoris* yeast.** C-RBD-H6  
694 PP (upper panel) or RBD-H6 HEK (lower panel) proteins were used for coating ELISA  
695 plates and for animal immunization. Sera and monoclonal antibodies were used in serial  
696 two-fold dilutions. (A,E). SS-1, SS4, SS-7 and SS-8 monoclonal antibodies; (B,F).  
697 COVID-19 sera from convalescents; (C,G) Sera from subjects immunized with Pfizer-  
698 BioNTech (red squares) and Sputnik vaccines (black triangles); (D,H). Mice (grey) and  
699 NHP (blue) sera; (I). C-RBD-H6 PP stimulates INF $\gamma$  secretion in CD3<sup>+</sup> cells from  
700 naturally infected individuals. Wilcoxon matched paired test.

701 **Fig. 9. Binding inhibition capacity of two independent protein preparations of the**  
702 **C-RBD-H6 PP (L04 and L07).** (A). The C-RBD-H6 PP protein displaced the hFc-RBD-  
703 HRP from the hFc-ACE2 coated ELISA plates, and (B) from the ACE2 receptor in Vero  
704 E6 cells. (C). The C-RBD-H6 PP protein was recognized by the soluble ACE2 receptor.



705 P64K-VEGFH6 and hFc-VEGFR2 non-related chimeric proteins were used as negative  
706 controls.

707 **Fig. 10. Immunogenicity of C-RBD-H6 PP protein in three animal species using**  
708 **different immunization routes and schedules.** (A) Evaluation of RBD-specific IgG in  
709 BALB/c mice 7 days after second and third intra-peritoneal immunization (n=10); (B).  
710 Evaluation in BALB/c mice of EC50 for the ACE2 binding inhibition and PRNT in the  
711 microneutralization assay (n=10); C. Correlation analyses of the ACE2 binding inhibition  
712 and microneutralization tests in mice (C). Spearman,  $r=0.6482$ ,  $p=0.0478$ ); (D).  
713 Evaluation of RBD-specific IgG in SD rats 3 days after 10 weakly subcutaneous  
714 immunization (n=10); (E). Evaluation in SD rats of EC50 for the ACE2 binding inhibition  
715 and PRNT in the microneutralization assay (n=20); (F). Correlation analyses of the  
716 ACE2 binding inhibition and microneutralization tests in rats (Spearman,  $r=0.9233$ ,  $p<$   
717  $0.0001$ ); (G). Evaluation of RBD specific IgG in NHP with 50  $\mu$ g and 100  $\mu$ g dose 14  
718 days after three subcutaneous immunizations every second week with 6 and 10 animals  
719 respectively; (H). Evaluation in NHP of EC50 for the ACE2 binding inhibition; (I).  
720 Evaluation in NHP of EC50 for the PRNT in the microneutralization assay. (J).  
721 Association Correlation analyses of the Inhibition and microneutralization tests in NHP  
722 (Spearman,  $r=0.8994$ ,  $p<0.0001$ ).

723 **Fig. 11. Heatmap of the cytokine response.** Splenocytes (A) and Lung CD3+  
724 enriched cells (B), after restimulation with C-RBD-H6 PP. Cells were obtained three  
725 months after the last immunization, from 4 to 5 mice per group that received three  
726 subcutaneous 25  $\mu$ g doses. Non-stimulated controls were subtracted from re-stimulated  
727 samples.

728 **Table 1.** Summary for the sequence verification of the N-deglycosylated C-RBD-H6 PP  
 729 considering the ESI-MS analysis of tryptic peptides generated by the in-solution buffer-  
 730 free digestion.  
 731

Code <sup>a)</sup>	$m/z_{Theor}$	z	$m/z_{Exp}$	Assignment
$C^{336}_-$ $C^{361}$ , Nt	1399.64	4	1399.63	$NWSFFSNIGGSSGGG$ - <sup>331</sup> <u>DITNLC</u> PFGEVFDATR <sup>346 b)</sup> / <sup>358</sup> ISNCVADYSVLYNSASFSTFK <sup>378</sup> (Native $C^{336}$ - $C^{361}$ , N-terminal end, Asn <sup>331</sup> and Asn <sup>343</sup> → Asp)
$C^{336}_-$ $C^{361}$ , Nt- NWSF	1266.09	4	1266.07	$FSNIGGSSGGG$ - <sup>331</sup> <u>DITNLC</u> PFGEVFDATR <sup>346 b)</sup> / <sup>358</sup> ISNCVADYSVLYNSASFSTFK <sup>378</sup> (Native $C^{336}$ - $C^{361}$ , N-terminal end -NWSF, Asn <sup>331</sup> and Asn <sup>343</sup> → Asp corresponding to the two N-glycosylation sites)
$F^{347}$ - $R^{355}$	557.28	2	557.26	<sup>347</sup> FASVYAWNR <sup>355</sup>
$K^{356}$ - $R^{357}$	303.21	1	303.20	<sup>356</sup> KR <sup>357</sup>
$C^{379}_-$ $C^{432}$	1020.81 765.86	3 4	1020.79 765.85	<sup>379</sup> CYGVSPTK <sup>386</sup>   <sup>425</sup> LPDDFTGCVIAWNSNNLDSK <sup>444</sup> (Native $C^{379}$ - $C^{432}$ )
$C^{379*}_-$ $C^{432}$	982.71	4	982.69	<sup>64</sup> CYGVSPTK <sup>71</sup>   <sup>418</sup> IADYNYKLPDDFTGCVIAWNSNNLDSK <sup>444</sup> (Native $C^{379}$ - $C^{432}$ , 1 missed cleavage)
$C^{391}_-$ $C^{525}$	992.52	4	992.47	<sup>387</sup> LNDLCFTNVYADSFVIR <sup>403</sup>   <sup>510</sup> VVLSFELLHAPATVCGPK <sup>528</sup> (Native $C^{391}$ - $C^{525}$ )
$G^{404}$ - $R^{408}$	575.28	1	575.27	<sup>404</sup> GDEVR <sup>408</sup>
$Q^{409}$ - $K^{417}$	450.25	2	450.24	<sup>409</sup> QIAPGQTGK <sup>417</sup>
$I^{418}$ - $K^{424}$	443.72	2	443.71	<sup>418</sup> IADYNYK <sup>424</sup>

V <sup>445</sup> - R <sup>454</sup>	609.80	2	609.78	<sup>445</sup> VGGNYNYLYR <sup>454</sup>
L <sup>455</sup> -R <sup>457</sup>	435.27	1	435.26	<sup>455</sup> LFR <sup>457</sup>
S <sup>459</sup> - R <sup>466</sup>	495.77	2	495.76	<sup>459</sup> SNLKPFER <sup>466</sup>
C <sup>480</sup> - C <sup>488</sup>	1589.38 1192.29	3 4	1589.35 1192.26	<sup>467</sup> DISTEIQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQP YR <sup>509</sup>  —————  (Native C <sup>480</sup> -C <sup>488</sup> )
Ct*-His <sub>6</sub>	799.68 600.01	3 4	799.67 600.00	<sup>529</sup> K-GGSGGSSSSSSSSSSSIEHHHHHH <sup>b)</sup> (C-terminal end, 1 missed cleavage)
Ct-His <sub>6</sub>	756.98 567.99	3 4	756.97 567.98	GGSGGSSSSSSSSSSSIEHHHHHH <sup>b)</sup> (C-terminal end)

732

733 Nt: N-terminal end, Ct-His<sub>6</sub>: His-tag C-terminal end. C<sup>#</sup>-C<sup>#</sup> corresponds to tryptic  
734 peptides linked either by intermolecular disulfide bonds or a tryptic peptide that contains  
735 an intramolecular disulfide bond in its structures.

736  $m/z_{\text{calc}}$  correspond to the calculated  $m/z$  values for all tryptic peptides generated by the  
737 in-solution buffer-free digestion of the N-deglycosylated protein.

738  $m/z_{\text{exp}}$  correspond to the experimental  $m/z$  values for all tryptic peptides observed in the  
739 ESI-MS analysis shown in Fig. 4.C.

740 Regions of the sequence written in italic do not correspond to the RBD of SRAS-CoV-2  
741 and were inserted in the cloning stage, while underlined residues indicate the  
742 conversion of N-glycosylated asparagines (Asn<sup>331</sup> and Asn<sup>343</sup>) into aspartic acid  
743 residues by the action of PNGase-F (Asn<sup>331</sup> and Asn<sup>343</sup>→Asp).

744

745 **Table 2.** Secondary structure content of the protein estimated by CD (BeStSel) and 3D  
746 coordinates (DSSP)

747

Secondary Structure Element	Secondary Structure Content, %	
	Method	
	BeStSel	DSSP
Helix	7.9	9.3
Beta antiparallel	28.7	22.4
Beta parallel	0.0	0.0
Turn	12.9	22.4
others	50.5	45.9
Helix1 (regular)	3.3	-
Helix2 (distorted)	4.6	-
Beta Antiparallel_1 (left-handed)	0.9	-
Beta Antiparallel_2 (relaxed)	12.0	-
Beta Antiparallel_3 (right-handed)	15.8	-

748

749 Reference List

750

751 [1] Pentón-Arias E, Muzio V., González-Griego M. The hepatitis B virus (HBV)  
752 infection and its prevention by a recombinant-DNA viral surface antigen (rec-  
753 HBsAg) vaccine. *Biotecnología Aplicada* 1994;11(1):1-11.

754 [2] Hardy E, Martínez E, Diago D, Díaz R, González D, herrera L. Large-scale  
755 Production of recombinant Hepatitis B Surface Antigen from *Pichia pastoris*.  
756 *Biotecnología Aplicada* 2000;17(1):52.

757 [3] Hernandez-Bernal F, Aguilar-Betancourt A, Aljovin V, et al. Comparison of four  
758 recombinant hepatitis B vaccines applied on an accelerated schedule in healthy  
759 adults. *Hum Vaccin* 2011 Oct;7(10):1026-36.

760 [4] Ministry of Public Health of Cuba. Statistical Yearbook. Infomed 2020 Available  
761 from: URL: [https://files.sld.cu/bvscuba/files/2020/05/Anuario-Electr%  
762 Espa%  
c3%  
b1ol-2019-ed-2020.pdf](https://files.sld.cu/bvscuba/files/2020/05/Anuario-Electr%c3%b3nico-Espa%c3%b1ol-2019-ed-2020.pdf)

763 [5] Kodati B, Darbha S. Mammalian Expression System and Improvisation for High  
764 Production. *International Journal of Science and Research* 2016;5(6):743-9.

765 [6] Barone PW, Wiebe ME, Leung JC, et al. Viral contamination in biologic  
766 manufacture and implications for emerging therapies. *Nat Biotechnol* 2020  
767 May;38(5):563-72.

- 768 [7] Rosano GL, Ceccarelli EA. Recombinant protein expression in Escherichia coli:  
769 advances and challenges. *Front Microbiol* 2014;5:172.
- 770 [8] Arbeitman CR, Auge G, Blaustein Ma, et al. Structural and functional comparison  
771 of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and  
772 mammalian cells. *Scientific Reports* 2020;10(1):21779.
- 773 [9] Karbalaee M, Rezaee SA, Farsiani H. Pichia pastoris: A highly successful  
774 expression system for optimal synthesis of heterologous proteins. *J Cell Physiol*  
775 2020 Sep;235(9):5867-81.
- 776 [10] Daly R, Hearn MT. Expression of heterologous proteins in Pichia pastoris: a useful  
777 experimental tool in protein engineering and production. *J Mol Recognit* 2005  
778 Mar;18(2):119-38.
- 779 [11] Wrapp D, Wang N, Corbett KS, et al. Cryo-EM Structure of the 2019-nCoV Spike  
780 in the Prefusion Conformation. *bioRxiv* 2020 Feb 15.
- 781 [12] Grant OC, Montgomery D, Ito K, Woods RJ. Analysis of the SARS-CoV-2 spike  
782 protein glycan shield reveals implications for immune recognition. *Sci Rep* 2020  
783 Sep 14;10(1):14991.

- 784 [13] Premkumar L, Segovia-Chumbez B, Jadi R, et al. The receptor binding domain of  
785 the viral spike protein is an immunodominant and highly specific target of  
786 antibodies in SARS-CoV-2 patients. *Sci Immunol* 2020 Jun 11;5(48).
- 787 [14] Pollet J, Chen WH, Versteeg L, et al. SARSCoV-2 RBD219-N1C1: A yeast-  
788 expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine  
789 stimulates virus neutralizing antibodies and T-cell immunity in mice. *Hum Vaccin*  
790 *Immunother* 2021 Apr 13;1-11.
- 791 [15] Chen WH, Wei J, Kundu RT, et al. Genetic Modification to Design a Stable Yeast-  
792 expressed Recombinant SARS-CoV-2 Receptor Binding Domain as a COVID-19  
793 Vaccine Candidate. *bioRxiv* 2021 Jan 1;2020.
- 794 [16] Espinosa LA, Ramos Y, Andújar I, et al. In-solution buffer-free digestion for the  
795 analysis of SARS-CoV-2 RBD proteins allows a full sequence coverage and  
796 detection of post-translational modifications in a single ESI-MS spectrum. *bioRxiv*  
797 2021 Jan 1;2021.
- 798 [17] Grote A, Hiller K, Scheer M, et al. JCat: a novel tool to adapt codon usage of a  
799 target gene to its potential expression host. *Nucleic Acids Res* 2005 Jul 1;33(Web  
800 Server issue):W526-W531.

801 [18] Higgins DR, Busser K, Comiskey J, Whittier PS, Purcell TJ, Hoeffler JP. Small  
802 vectors for expression based on dominant drug resistance with direct multicopy  
803 selection. *Methods Mol Biol* 1998;103:41-53.

804 [19] Gurramkonda C, Polez S, Skoko N, et al. Application of simple fed-batch technique  
805 to high-level secretory production of insulin precursor using *Pichia pastoris* with  
806 subsequent purification and conversion to human insulin. *Microb Cell Fact* 2010  
807 May 12;9:31.

808 [20] Betancourt LH, Espinosa LA, Ramos Y, et al. Targeting the hydrophilic regions of  
809 recombinant proteins by MS via in-solution buffer-free trypsin digestion. *Eur J*  
810 *Mass Spectrom (Chichester )* 2020 Jun;26(3):230-7.

811 [21] Micsonai A, Wien F, Kernya L, et al. Accurate secondary structure prediction and  
812 fold recognition for circular dichroism spectroscopy. *Proc Natl Acad Sci U S A* 2015  
813 Jun 16;112(24):E3095-E3103.

814 [22] Micsonai A, Bulyaki E, Kardos J. BeStSel: From Secondary Structure Analysis to  
815 Protein Fold Prediction by Circular Dichroism Spectroscopy. *Methods Mol Biol*  
816 2021;2199:175-89.

817 [23] Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition  
818 of hydrogen-bonded and geometrical features. *Biopolymers* 1983  
819 Dec;22(12):2577-637.



- 820 [24] Vriend G. WHAT IF: a molecular modeling and drug design program. J Mol Graph  
821 1990 Mar;8(1):52-6, 29.
- 822 [25] Wang Q, Zhang Y, Wu L, et al. Structural and Functional Basis of SARS-CoV-2  
823 Entry by Using Human ACE2. Cell 2020 May 14;181(4):894-904.
- 824 [26] Suthar MS, Zimmerman MG, Kauffman RC, et al. Rapid Generation of Neutralizing  
825 Antibody Responses in COVID-19 Patients. Cell Rep Med 2020 Jun  
826 23;1(3):100040.
- 827 [27] Robbiani DF, Gaebler C, Muecksch F, et al. Convergent antibody responses to  
828 SARS-CoV-2 in convalescent individuals. Nature 2020 Aug;584(7821):437-42.
- 829 [28] Piccoli L, Park YJ, Tortorici MA, et al. Mapping Neutralizing and Immunodominant  
830 Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided  
831 High-Resolution Serology. Cell 2020 Nov 12;183(4):1024-42.
- 832 [29] Goel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell  
833 responses in SARS-CoV-2 naive and recovered individuals following mRNA  
834 vaccination. Sci Immunol 2021 Apr 15;6(58).
- 835 [30] Luong M, Lam JS, Chen J, Levitz SM. Effects of fungal N- and O-linked  
836 mannosylation on the immunogenicity of model vaccines. Vaccine 2007 May  
837 30;25(22):4340-4.

838 [31] Shang J, Ye G, Shi K, et al. Structural basis of receptor recognition by SARS-CoV-  
839 2. Nature 2020 May;581(7807):221-4.

840 [32] Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding  
841 domain bound to the ACE2 receptor. Nature 2020 May;581(7807):215-20.

842 [33] Sui J, Deming M, Rockx B, et al. Effects of human anti-spike protein receptor  
843 binding domain antibodies on severe acute respiratory syndrome coronavirus  
844 neutralization escape and fitness. J Virol 2014 Dec;88(23):13769-80.

845 [34] D'Alessio C, Caramelo JJ, Parodi AJ. UDP-Glc:glycoprotein glucosyltransferase-  
846 glucosidase II, the ying-yang of the ER quality control. Semin Cell Dev Biol 2010  
847 Jul;21(5):491-9.

848

849

850 **Appendix. Other co-authors in the Study**

851 **Center for Genetic Engineering and Biotechnology**

852 Isela María García Tamayo

853 Yahima Chacón Quintero

854 Ricardo Ulises Martínez Rosales

855 Dionne Casillas Casanova

856 Ailyn de la Caridad Ramón Sánchez

857 Lizet Aldana Velazco

858 Jorge Castro Velazco

859 **Civilian Defense Scientific Research Center**

860 Juliet María Enriquez Puertas, M.Sc.

861 Mireida Rodríguez Acosta, M.D., Ph.D.

862 Enrique Noa Romero, Ph.D.

863 Nibaldo Luis González Sosa, M.Sc.


864 Marta Dubed Echevarría, M.Sc.

865





**A**


V A B C




**B**

V A B C























—○— C-RBD-H6 PP









—○— C-RBD-H6 PP

C-RBD-H6\_PP



C-RBD-H6\_HEK-293











**A**

medRxiv preprint doi: <https://doi.org/10.1101/2021.06.29.21259605>; this version posted July 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




	hFc-RBD Biot	Streptavidin HRP
Neg control Fluorescence	-	+
+ve control hFc-ACE2	+	+
+ve control hFc-RBD 100ug/mL	+	+
L04 C-RBD-H6 PP 100 ug/mL	+	+
L07 C-RBD-H6 PP 100 ug/mL	+	+
+ve control Fluorescence	+	+
Neg control P64K-VEGFH6	+	+


**B****C**



**D**



**E**



**F**

